uploads/2017/12/Invokana.png

How Did Invokana Perform in 3Q17?

By

Updated

Invokana revenue trends

In 3Q17, Johnson & Johnson’s (JNJ) Invokana generated revenues of $265 million, a ~19% decline on a year-over-year (or YoY) basis and a 10% decline quarter-over-quarter. In 3Q17, in the US and outside the US markets (international markets), Invokana generated revenues of $220 million and $45 million, respectively, compared to $294 million and $34 million in 3Q16. Invokanna reported year-to-date (or YTD) September 2017 revenues of $844 million compared to $1.0 billion in the corresponding period in 2016.

Article continues below advertisement

About Invokana

Invokana (canagliflozin) is used for the treatment of individuals with type two diabetes mellitus. In November 2017, Johnson & Johnson presented new analysis from the CANVAS program. Invokana showed a decrease in the risk of cardiovascular outcomes in individuals with and without a history of cardiovascular disease.

In clinical trials, Invokana demonstrated a decrease in the risk of hospitalization due to heart failure (or HHF) in both groups of patients with a history of cardiovascular disease and those with only risk factors for cardiovascular disease. In both the patient groups, Invokana achieved a reduction in the risk of the composite renal endpoint.

In November 2017, Johnson & Johnson also presented the results from the EASEL trial. In the EASEL trial, adult patients on Invokana or other sodium glucose cotransporter-2 inhibitor (or SGLT2i) demonstrated 43% reduction in the risk of all-cause mortality (or ACM) and hospitalization for heart failure (or HHF) after around a mean 1.6 years versus patients on non-SGLT2i drugs. Further, patients on SGLT2i therapy demonstrated a 33% reduced risk of MACE (major adverse cardiovascular events).

Invokana’s peers in the antidiabetic drugs market include Eli Lilly’s (LLY) Jardiance, AstraZeneca’s (AZN) Farxiga, and Novo Nordisk’s (NVO) Victoza. In 3Q17, Jardiance and Farxiga reported revenues of $103 million and $285 million, respectively. The PowerShares Dynamic Pharmaceuticals Portfolio (PJP) invests ~5.0% of its total portfolio holding in Johnson & Johnson.

Advertisement

More From Market Realist